Introduction
============

Hepatocellular carcinoma (HCC) is among the most common types of malignant tumor, and ranked fifth globally in terms of incidence. It is also the third most common cause of cancer-associated mortality worldwide ([@b1-ol-0-0-8666]). HCC has an incidence of \~466,100/year in China, according to a 2015 study by The National Central Cancer Registry of China ([@b2-ol-0-0-8666]). Surgical resection is the first-line treatment for patients with early-stage HCC, which can be curative ([@b3-ol-0-0-8666],[@b4-ol-0-0-8666]). However, the rate of metastasis and recurrence following surgery remains high, which is a major obstacle for improving the clinical outcome of patients with HCC ([@b5-ol-0-0-8666]). Evidence suggests that tumor recurrence and metastasis are associated with cancer stem cells (CSCs) in various types of cancer, including HCC ([@b6-ol-0-0-8666]). CSCs are reported to have inherent tumor initiating potential, serving important roles in tumor relapse, driving primary tumor growth, and the seeding and establishment of metastases ([@b7-ol-0-0-8666]). Recently, CSCs have been investigated as a therapeutic target.

Clinical observations and experimental data have indicated heterogeneity among cancer cell lines in terms of aggressive potential, suggesting that CSCs from different sourced may have varying migration ability ([@b8-ol-0-0-8666]--[@b10-ol-0-0-8666]). A previous study demonstrated that the percentage of CSCs was positively correlated with the metastatic potential of the parent cell line ([@b11-ol-0-0-8666]). However, it remains to be determined whether CSCs derived from different cell lines/tumors possess different metastatic capabilities. Side population (SP) cells, are a subset of cells with the ability to efflux Hoechst 33342 in flow cytometry through an ATP-binding cassette (ABC) membrane transporter, and were first described by Goodell *et al* ([@b12-ol-0-0-8666]) in the bone marrow. SP cells isolated from various cancer cell lines have been demonstrated to exhibit stem cell-like properties ([@b13-ol-0-0-8666]--[@b16-ol-0-0-8666]). In the present study, SP cells were employed as a model to study the molecular differences in the metastatic potential of CSCs derived from different cell lines.

High-throughput quantitative proteomic technologies provide a powerful tool for systematically characterizing the overall proteome alterations underlying physiological or pathological changes. Isobaric tags for relative and absolute quantification (iTRAQ) is an ultrasensitive and precise approach for studying protein quantitative changes in ≤8 samples simultaneously ([@b17-ol-0-0-8666],[@b18-ol-0-0-8666]). Comparative proteomic approaches coupled with iTRAQ are widely used to investigate the molecular mechanisms of tumorigenesis, metastasis and recurrence of HCC ([@b19-ol-0-0-8666]--[@b21-ol-0-0-8666]). iTRAQ-based quantitative study of protein expression profiles between CSCs and their parental cell lines have also been reported ([@b22-ol-0-0-8666]). However, to the best of our knowledge, the application of iTRAQ labeling in studying the molecular differences among CSCs from cell lines with different metastatic potentials has not been previously reported. In the present study, an iTRAQ based quantitative proteomic approach was used to systematically compare the overall proteome profiles among different SP cells to reveal the underlying molecular mechanisms of HCC cell lines with different metastatic potentials.

Materials and methods
=====================

### Cell culture

The human HCC HCCLM3, MHCC97-H and MHCC97-L cell lines were purchased from The Cell Bank of Type Culture Collection of Chinese Academy of Science, Shanghai Institute for Biological Sciences (Shanghai, China). The HCC cell line, Hep3B, was purchased from the America Type Culture Collection (Manassas, VA, USA). HCCLM3, MHCC97-H, MHCC97-L cells were cultured in high-glucose DMEM containing 10% FBS, 100 U⁄ml penicillin and 100 µg⁄ml streptomycin (all reagents from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Hep3B was cultured in MEM (Gibco; Thermo Fisher Scientific, Inc.) with 10% FBS. All cells were incubated at 37°C in a humidified atmosphere containing 5% CO~2~.

### Flow cytometry (FCM) analysis of SP cells

The 4 cell lines were cultured to 80% confluence and detached using 0.25% Trypsin-EDTA, then suspended in DMEM supplemented with 3% FBS, at a density of 1×10^6^ cells/ml. The cells were then incubated with 20 µg/ml Hoechst 33342 (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) alone or with 25 µg/ml verapamil (Sigma-Aldrich; Merck KGaA) at 37°C for 90 min. Verapamil was used as a guiding parameter to determine the boundary between SP and main population (MP) cells. The samples were centrifuged at 300 × g for 5 min at 4°C, and then re-suspended in PBS supplemented with 3% FBS. Propidium iodide (PI; Sigma-Aldrich; Merck KGaA) was added at 1 µg/ml to exclude analysis of any dead cells. FCM analysis was performed using a Moflo XDP flow cytometer (Beckman Coulter, Inc., Brea, CA, USA), as previously described ([@b23-ol-0-0-8666]). Each assay was performed in triplicate.

### Sphere formation assay and soft agar colony formation assay

For the sphere formation, SP and MP cells sorted from the 4 cell lines were suspended separately in serum-free DMEM/F12 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 20 ng/ml epidermal growth factor, 10 ng/ml basic fibroblast growth factor and 10 µl/ml B27 (all from Gibco; Thermo Fisher Scientific, Inc.). The cells were then plated into 6-well UltraLow Attachment plates (Corning Incorporated, Corning, NY, USA) at 2×10^3^ cells/well. After 14 days, the number of spheres were counted under a confocal microscope (magnification, ×50). For the soft agar colony formation assay, sorted SP and MP cells were seeded into 6-well plates at 5×10^3^ cells/well in 0.3% agarose (Promega Corporation, Madison, WI, USA) over a 0.6% agarose layer. After 14 days, the number of colonies were counted under confocal microscope (magnification, ×50).

### Cell migration assay

The migration assays were performed using Transwell plates (pore diameter, 8-µm; Corning Incorporated), according to the manufacturer\'s instructions. A total of 100 µl SP and MP cells at 1×10^6^ cells/ml were cultured in the upper chamber in serum-free DMEM supplemented with 0.5% BSA. A total of 600 µl DMEM supplemented with 10% FBS was added to the lower chamber. After 48 h, non-migrating cells on the upper surface of the filters were removed with cotton swabs, and cells on the lower membrane of the filters were fixed with 4% paraformaldehyde, and stained with 0.1% hematoxylin (Beyotime Institute of Biotechnology, Haimen, China) for 20 min at room temperature. The stained cells, which had passed through the filter to the lower surface, were counted under a confocal microscope in 5 randomly selected fields of view (magnification, ×200).

### Protein preparation and iTRAQ labeling

A total of 500 µl lysis buffer \[8 M urea (Sigma-Aldrich, Merck KgaA), 50 mM NH~4~HCO~3~, 50 mM iodoacetamide (IAA) and 1X protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland)\] was added to the 4 types of SP and MP cells, followed by sonication for 8 min with a period of 1 sec sonication and 5 sec pause at 190 W on ice. Following centrifugation at 17,000 × g for 10 min at 4°C, the supernatant was collected. The protein concentration of the supernatant was determined by BCA assay (TransGen Biotech, Co., Ltd., Beijing, China), according manufacturer\'s protocol. Then, 100 µg protein was adjusted to a final volume of 100 µl in 100 mM triethylammonium bicarbonate (TEAB). A total of 8 µl DTT (1M) was added to the protein samples and incubated at 55°C for 1 h, followed by the addition of 10 µl 500 mM IAA, and another incubation for 30 min in the dark at room temperature to alkylate the proteins. The proteins were re-dissolved in 100 µl TEAB (100 mM), and then digested by sequence-grade modified trypsin (Promega Corporation) at 37°C for 16 h, and the resultant peptide mixture was labeled using chemicals from the iTRAQ reagent kit (cat. no. 4381663, Sigma-Aldrich Merck KGaA), according to the manufacturer\'s protocol. The peptides from Hep3B, MHCC97-L, MHCC97-H and HCCLM3 MP cells were labeled with 113, 115, 117 and 119 isobaric tags, respectively; and the peptides from the SP cells of the 4 HCC cell lines were labeled with 114, 116, 118 and 121 isobaric tags, respectively. Equal amounts of labeled samples were mixed together, and desalted in Sep-Pak Vac C18 cartridges (Waters Technologies Corporation, Milford, MA, USA) and dried in a vacuum centrifuge.

### High pH reverse phase separation and low pH two dimensional-liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS) analysis

The peptide mixture was re-dissolved in solution A (10% acetonitrile (ACN) in water, pH 10.0), and fractionated by high pH separation using a 1260 Infinity LC system (Agilent Technologies, Inc., Santa Clara, CA, USA) connected to a reverse phase column (Durashell C18, 5 µm, 4.6×250 mm; Phenomenex^®^, Torrance, CA, USA). High pH separation was performed with a linear gradient of 0--80% solution B (95% ACN in water, pH 10.0) for 80 min at a flow rate of 700 µl/min. Following separation, the column was re-equilibrated with solution A for 15 min. A total of 10 fractions were collected and dried in a vacuum concentrator. The fractions were analyzed using an EASY-nLC1000 system (Thermo Fisher Scientific, Inc.) connected to a Q Exactive Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Inc.) equipped with an online nano-electrospray ion source. Each fraction was re-suspended in 80 µl solution C (0.1 % formic acid in water). The samples were then separated by nano-LC and analyzed using the online electrospray tandem mass spectrometry as follows. A total of 10 µl peptide sample was loaded onto a trap column (Acclaim PepMap C18, 100 µm × 2 cm; Thermo Scientific, Inc.). Subsequently, it was separated in an analytical column (Acclaim PepMap C18, 75 µm × 15 cm) with a linear gradient of 2--80% solution D (0.1 % formic acid in ACN) over 2 h with a flow rate of 300 nl/min at 40°C. Finally, the column was re-equilibrated with solution C for 15 min. The solutions A, B, C and D were all produced in-house. The Q-Exactive mass spectrometer was operated in the data dependent mode to switch mechanically between MS and MS/MS acquisitions. MS spectra (m/z 300--1,500) were acquired with a mass resolution of 70,000 HZ, followed by 20 sequential high energy collisional dissociation MS/MS scans with a resolution of 17,500 HZ. One microscan was recorded using a dynamic exclusion of 20 sec for all cases.

### Database searching and criteria

Protein identification was performed using Proteome Discoverer (version 1.4; Thermo Fisher Scientific, Inc.) against a database provided by The Universal Protein Resource ([www.uniprot.org/uniprot](www.uniprot.org/uniprot); released, 2014-04-10). The enzyme specificity of trypsin was used and ≤2 missed cleavages were allowed for protease digestion. Proteome Discoverer was searched with a parent ion tolerance of 10 parts per million and a fragment ion mass tolerance of 0.02 Da. Carboxymethyl of cysteine was specified as a fixed modification. iTRAQ modification of peptide N-terminus, oxidation of methionine, deamination of asparagine and glutamine, and iTRAQ 8-plex labeling of lysine and tyrosine residues were set as variable modifications. Scaffold software (version 4.4.5; Proteome Software Inc., Portland, OR, USA) was used to estimate the false discovery rate (FDR) and validate the MS/MS-based peptide and protein identifications. The proteins were assembled using the parsimony method and accepted with a peptide FDR \<1% and a protein probability \>90%. Proteins containing similar peptides, which could not be distinguished based on MS/MS analysis alone, were grouped to satisfy the principles of parsimony. All results were then exported into Excel 2010 (Microsoft Corporation, Redmond, WA, USA) for data interpretation. To identify the differentially expressed proteins (DEPs), the relative protein expression values were compared among the 4 SP cell groups. The proteins were considered to be differentially expressed if the iTRAQ ratios were \>1.5 or \<0.67 when LM3-SP/MP cells were compared with Hep3B-SP/MP cells. The DEPs of SP and MP were analyzed using a Venn diagram (<http://bioinformatics.psb.ugent.be/webtools/Venn/>), and trends in the expression values of the DEPs of SP cells specially were analyzed using Excel 2010 (Microsoft Corporation, Redmond, WA, USA). The protein expression levels that were upregulated or downregulated with increasing metastatic potential in the 4 HCC SP cell groups are summarized in [Table I](#tI-ol-0-0-8666){ref-type="table"}.

### Functional analysis of the differentially expressed proteins

The Gene Ontology (GO) annotation and pathway enrichment analysis of the differentially expressed proteins and clustered proteins was performed using the Database for Annotation, Visualization and Integrated Discovery (<https://david.ncifcrf.gov/>). GO annotation included biological processes, cellular components and molecular functions. The biological function and signaling pathway annotations of the differentially expressed proteins were analyzed by Ingenuity Pathway Analysis (IPA) software (version 7.5, Qiagen GmbH, Hilden Germany). The GO annotations were ranked in terms of the level of enrichment of the differentially expressed proteins.

### Statistical analysis

All data are expressed as the mean ± standard deviation. Statistical analysis was performed using one-way analysis of variance followed by Tukey\'s test. P\<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using SPSS software (version 17; SPSS, Inc., Chicago, IL, USA).

Results
=======

### Identification and characterization of SP cells

97-L, 97-H and LM3 cell lines possess identical genetic backgrounds and progressively increased metastatic potential ([@b24-ol-0-0-8666]). The Hep3B cell line has low metastatic potential. These cell lines have been used widely in the study of the HCC metastasis ([@b24-ol-0-0-8666],[@b25-ol-0-0-8666]). In the present study, the 4 HCC cell lines were analyzed by dual wavelength fluorescence-activated cell sorting following incubation with Hoechst 33342. Representative results are presented in [Fig. 1A](#f1-ol-0-0-8666){ref-type="fig"}, the proportion of SP cells in Hep3B, 97-L, 97-H, and LM3 were 0.79, 2.27, 4.21 and 6.03%, respectively. The proportion of SP cells increased with the metastatic potentials of their parent cell lines, which is consistent with previous reports.

To assess the CSC characteristics of the sorted SP and MP cells, they were subjected to a sphere formation assay. On day 3, sorted SP cells began to form spheres, whereas MP cells formed no floating spheres and eventually died. Upon spheres dispersal into single cells, secondary and tertiary spheres also formed. SP cells of the 4 cell lines demonstrated a similar ability to form spheres ([Fig. 1B](#f1-ol-0-0-8666){ref-type="fig"}).

In order to compare self-renewing capacity, the sorted SP and MP cells were subjected to soft agar colony formation assays. After 2 weeks, there was no significant difference in terms of colony number among SP cells derived from the different cell lines ([Fig. 1C and D](#f1-ol-0-0-8666){ref-type="fig"}).

To assess metastatic ability, the sorted SP and MP cells were subjected to a Transwell migration assay. SP cells exhibited a high metastatic ability compared with MP cells. Furthermore, the metastatic ability increased progressively from Hep3B-SP to 97L-SP, to 97H-SP, to LM3-SP cells ([Fig. 1E and F](#f1-ol-0-0-8666){ref-type="fig"}).

### Proteomic analysis of the SP cells and relative quantification of proteome of the side population cells

A quantitative MS-based discovery strategy was applied to study the overall proteome of SP cells. Total proteins extracted from the cells were analyzed using iTRAQ and 2D-LC-MS/MS, and the workflow is illustrated in [Fig. 2](#f2-ol-0-0-8666){ref-type="fig"}. Scaffold software was used to identify a total of 1,670 proteins ([Fig. 3A](#f3-ol-0-0-8666){ref-type="fig"}), then GO annotation was applied. As summarized in [Fig. 3B](#f3-ol-0-0-8666){ref-type="fig"}, the top 3 molecular functions associated with the identified proteins were 'translation', 'RNA processing' and 'protein localization'.

### Expression trends of proteins and GO analysis

To systematically analyze the molecular differences between SP cell groups, the relative protein expression values were compared. A mean fold change of \>1.5 or \<0.67 in relative protein expression between LM3 and Hep3B cells was indicative of differential expression. A total of 198 differentially expressed proteins (DEPs; 57 upregulated and 141 downregulated) were identified when LM3-SP cells were compared with Hep3B-SP cells; 98 DEPs (48 upregulated and 50 downregulated) were identified when LM3-MP cells were compared with Hep3B-MP cells. The DEPs of SP (198 DEPs) and MP (98 DEPs) were analyzed using a Venn diagram. There were 47 joint DEPs appeared in both SP and MP cells. Furthermore, there were 51 DEPs observed in MP cells and 151 DEPs were observed in the SP cells ([Fig. 3C](#f3-ol-0-0-8666){ref-type="fig"}), suggesting that there may be different molecular mechanisms between SP and MP cells in HCC.

Furthermore, the relative protein levels of 151 DEPs observed in the SP cells were analyzed using Excel 2010. There were 8 trends identified according to the the relative protein level of Hep3B-SP, 97L-SP, 97H-SP and LM3-SP. A number of DEPs increased progressively in expression from Hep3B-SP to LM3-SP ([Fig. 4A](#f4-ol-0-0-8666){ref-type="fig"}) and a number of DEPs decreased progressively from Hep3B-SP to LM3-SP ([Fig. 4H](#f4-ol-0-0-8666){ref-type="fig"}). The expression of other DEPs altered non-linearly between groups ([Fig. 4B-G](#f4-ol-0-0-8666){ref-type="fig"}). A total of 11 and 19 differentially expressed proteins (DEPs) were upregulated and downregulated, respectively, with increasing metastatic potentials ([Table I](#tI-ol-0-0-8666){ref-type="table"}). These 30 DEPs formed clearly distinct clusters, as illustrated in the heatmap in [Fig. 4I](#f4-ol-0-0-8666){ref-type="fig"}, and were mainly involved in 'regulation of mRNA processing' and 'cytoskeleton organization' biological processes according to GO analysis ([Fig. 4J](#f4-ol-0-0-8666){ref-type="fig"}). Furthermore, the majority of these proteins were involved in the process of 'self-renewal', 'chemoresistance' and 'metastasis' in various types of cancer, and they may promote HCC migration in a synergistic manner. Transketolase (TKT) has been demonstrated to promote cell proliferation and metastasis in various types of cancer and is associated with poor survival of patients with HCC ([@b26-ol-0-0-8666]--[@b28-ol-0-0-8666]). Targeting TKT has been demonstrated to lead to increased oxidative stress, causing increased sensitivity of cancer cells to therapeutic treatments, including Sorafenib ([@b29-ol-0-0-8666]). ATP binding cassette subfamily C member 1 ([@b30-ol-0-0-8666]), integrin subunit β1 (ITGB1) ([@b31-ol-0-0-8666],[@b32-ol-0-0-8666]) and aldo-keto reductase family 1 member B ([@b33-ol-0-0-8666],[@b34-ol-0-0-8666]) have been reported to be involved in chemoresistance/radioresistance and cancer metastasis. P21-activated kinase 2 ([@b35-ol-0-0-8666]), G protein nucleolar 3 ([@b36-ol-0-0-8666]), nucleophosmin ([@b37-ol-0-0-8666]) and pericentriolar material 1 ([@b38-ol-0-0-8666]) have been associated with metastatic characteristics in various types of cancer. These results indicate that different SP cells may have different molecular mechanisms for metastatic initiation, regulation, and evasion of conventional HCC chemotherapies.

### Pathways and networks identified by IPA analysis

To further elucidate the possible molecular mechanisms of tumorigenesis and metastasis of SP cell groups, IPA software was used to analyze the signaling pathways in which the DEPs were involved. The IPA analysis demonstrated that the majority of the 30 DEPs altered linearly between SP cell groups were involved in the regulation of AKT and nuclear factor-κB (NF-κB) signaling ([Fig. 5](#f5-ol-0-0-8666){ref-type="fig"}). AKT signaling is associated with the regulation of cell proliferation, differentiation, apoptosis and glucose transport ([@b39-ol-0-0-8666]). The AKT signaling pathway is also associated with cell invasion and migration ([@b40-ol-0-0-8666]). Cluster of differentiation (CD)133 has been demonstrated to promote gallbladder carcinoma cell migration by activating AKT phosphorylation ([@b41-ol-0-0-8666]). The AKT signaling pathway has been associated with CSC-like properties and epithelial-mesenchymal transition (EMT) features of A549/CDDP cells ([@b42-ol-0-0-8666]). In the network assembled in the present study, ITGB1 was indicated to affect AKT indirectly, and TKT and CP are downstream of AKT signaling. Furthermore, NF-κB signaling is central to the network. It has been reported that the NF-κB signaling contributes to the invasive and metastatic capabilities of CSCs through modulation of the extracellular environment or through cell-intrinsic changes, including EMT ([@b43-ol-0-0-8666],[@b44-ol-0-0-8666]). Therefore, the results of the present study suggest that in HCC, AKT and NF-κB signaling may contribute to the regulation of HCC metastasis through regulating the DEPs expressed in CSC-like SP cells. These results suggest that the quantitative proteomics approach used was suitable for studying the overall molecular profile changes of different SP cells in HCC, and provide insight into the potential molecular mechanisms of this effect.

Discussion
==========

Although surgical resection has been the first-line treatment for HCC in recent decades, the prognosis of HCC patients remains poor ([@b45-ol-0-0-8666]). Post-surgical metastasis and recurrence are the main causes of the high mortality rate and poor prognosis of HCC ([@b46-ol-0-0-8666]). To achieve a longer survival time, the identification of novel therapeutic targets associated with HCC invasion and metastasis is required. CSCs are thought to cause cancer development, and to be the primary cause of tumor relapse and metastasis ([@b47-ol-0-0-8666]). Thus, CSC-targeted therapeutic approaches may have great potential in HCC.

CSCs have been identified in several types of malignant tumor, including breast ([@b48-ol-0-0-8666]), brain ([@b49-ol-0-0-8666]), prostate ([@b50-ol-0-0-8666]), lung ([@b51-ol-0-0-8666]), gastric ([@b52-ol-0-0-8666]), colon ([@b53-ol-0-0-8666]) and pancreatic ([@b54-ol-0-0-8666]) cancers, as well as melanoma ([@b55-ol-0-0-8666]). Recently, research has revealed the existence of CSCs in HCC ([@b56-ol-0-0-8666]). With the exception of SP identification, several surface markers are used including CD133 ([@b57-ol-0-0-8666]), CD90 ([@b58-ol-0-0-8666]), CD44 ([@b59-ol-0-0-8666]), epithelial cell adhesion molecule ([@b60-ol-0-0-8666]), oval cell marker 6 ([@b61-ol-0-0-8666]), and aldehyde dehydrogenase ([@b62-ol-0-0-8666]) are employed. Although cells expressing different combinations of these markers possess CSC properties, heterogeneity in metastatic potential is observed. It was reported that CD90+CD44+ cells demonstrated a more aggressive phenotype compared with CD90+CD44-cells, and formed metastatic lesions in the lungs of immunodeficient mice ([@b58-ol-0-0-8666]). CD133+CD44+ HCC cells isolated from HCC cell lines have been demonstrated to exhibit an improved ability to initiate tumor formation and lung metastasis compared with CD133+CD44-cells ([@b63-ol-0-0-8666]).

In the present study, SP cells were isolated from 4 HCC cell lines and their abilities to self-renew and migrate were compared. The results demonstrate that SP cells from different HCC lines possess similar self-renewing abilities and differing metastatic potentials, which is consistent with the results of previous studies ([@b64-ol-0-0-8666],[@b65-ol-0-0-8666]). Furthermore, through a comprehensive analysis of DEPs, significant differences among the 4 SP cell groups were demonstrated at the proteome level. The expression levels of 11 and 19 proteins were upregulated and downregulated, respectively, with increased metastatic potential. The majority of these proteins were demonstrated to be involved in 'cell proliferation', 'migration' and 'invasion of cancer', and they may promote HCC metastasis in a synergistic manner. This hypothesis was supported by the results of IPA analysis, which indicated alteration of the AKT and NF-κB signaling pathways, which have been demonstrated to be associated with the regulation of migration and invasion in a number of types of cancer ([@b66-ol-0-0-8666]--[@b68-ol-0-0-8666]).

Numerous markers have been identified which are indicative of CSCs in the context of HCC. However, such cells exhibit significant heterogeneity between laboratories ([@b69-ol-0-0-8666]). The proportion of cells expressing specific markers also varies between HCC cell lines. For example, CD133+ cells cannot be detected in numerous HCC cell lines and clinical HCC samples ([@b11-ol-0-0-8666]). SP cells are also heterogeneous; however, they are mainly identified by the expression of ABC transporters, including ABCB1 and ABCG2 ([@b70-ol-0-0-8666]). SP identification provides an alternative method of identification when definite markers of CSCs are uncharacterized. There are limitations to all CSC isolation strategies, therefore, a combination of different isolation methods may be required.

To the best of our knowledge, this is the first report to investigate the overall proteome variations among SP cells from HCC cell lines with different metastatic potentials. The present study provides novel information regarding of the metastatic potential of CSCs, which will facilitate further investigation. Further research, such as a genomic-transcriptomic combination study, is required to fully elucidate the underlying molecular mechanisms of CSC metastatic potential.
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![Identification of side population cells and the characteristics of each subpopulation. (A) Identification of SP cells by flow cytometry in the HCC cell lines, Hep3B, MHCC97L, MHCC97H and HCCLM3. (B) SP and MP cells were cultured in serum-free medium for 2 weeks (×50, magnification) to analyze sphere formation. (C) Representative images of the soft agar colony formation assays, in which SP and MP cells were seeded into a 6-well plate at 5×10^3^ cells/well in 0.3% agarose over a 0.6% agarose bottom layer for 2 weeks (×50, magnification). (D) Quantification of the colony formation assay demonstrated there was no significant difference in self-renewal ability among SP cells derived from the different cell lines. (E) Representative images of migration assay. (F) Quantification of the migration assay revealed that the metastatic abilities of SP cells from the different cell lines increased progressively from Hep3B-SP to 97L-SP, to 97H-SP, to LM3-SP. SP, side population; HCC, hepatocellular carcinoma; MP, main population; 97L, MHCC97-L; 97H, MHCC97-H; LM3, HCCLM3. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001.](ol-16-01-0335-g00){#f1-ol-0-0-8666}

![The workflow of the proteomic study. SP and MP cells were subjected to tryptic digestion, labeled with iTRAQ reagents, and combined for fractionation, followed by LC-MS/MS and data analysis. SP, side population; MP, main population; iTRAQ, isobaric tags for relative and absolute quantification; 2D LC-MS/MS, two-dimensional liquid chromatography-tandem mass spectrometry.](ol-16-01-0335-g01){#f2-ol-0-0-8666}

![Features of the SP cell proteome dataset revealed by isobaric tags for relative and absolute quantification analysis. (A) Analysis of the relative protein level revealed a protein abundance dynamic range of 7 orders of magnitude. (B) Results of Gene Ontology analysis. (C) Venn diagrams demonstrate the total number of DEPs in the SP and MP groups when LM3-SP cells were compared with Hep3B-SP cells and LM3-MP cells were compared with Hep3B-MP cells. SP, side population; DEP, differentially expressed protein; MP, main population; LM3, HCCLM3.](ol-16-01-0335-g02){#f3-ol-0-0-8666}

![Expression trends, hierarchical clustering and biological processes analysis of the DEPs. Expression trends of 151 DEPs in SP cells. (A) The relative protein level of DEPs increased progressively from Hep3B-SP to 97L-SP, to 97H-SP, to LM3-SP cells. (B-G) Types are the proteins which are altered non-linearly. (B) The relative protein level of DEPs follows the trend of Hep3B-SP\< 97L-SP\< 97H-SP \>LM3-SP. (C) The relative protein level of DEPs follows the trend of Hep3B-SP\< 97L-SP \>97H-SP\< LM3-SP. (D) The relative protein level of DEPs follows the trend of Hep3B-SP\< 97L-SP \>97H-SP\> LM3-SP. (E) The relative protein level of DEPs a follows the trend of Hep3B-SP \>97L-SP\< 97H-SP\< LM3-SP. (F) The relative protein level of DEPs follows the trend of Hep3B-SP \>97L-SP \<97H-SP \>LM3-SP. (G) The relative protein level of DEPs follows the trend of Hep3B-SP \>97L-SP \>97H-SP\< LM3-SP. (H) The relative protein level of DEPs decreased progressively from Hep3B-SP to LM3-SP cells. (I) Hierarchical clustering analysis of the 30 DEPs that were upregulated or downregulated with increasing metastatic potentials. The relative protein level of DEPs are presented: Red indicates a relative protein level \>1 and green indicates a relative protein level \<1. (J) Gene Ontology analysis of the 30 DEPs in terms of biological processes. DEPs, differentially expressed proteins; SP, side population; 97L, MHCC97-L; 97H, MHCC97-H; LM3, HCCLM3.](ol-16-01-0335-g03){#f4-ol-0-0-8666}

![The AKT and NF-κB signaling pathways were demonstrated to be involved in the function of SP-cell derived from all 4 cell lines. Red indicates the upregulated proteins and green indicates the downregulated proteins. Solid lines indicate direct interactions and dotted lines indicate indirect interactions.](ol-16-01-0335-g04){#f5-ol-0-0-8666}

###### 

Differentially expressed proteins among SP cells with increasing metastatic potentials.

  Accession number   Protein name                                              iTRAQ ratio (97-L SP/Hep3B SP)   iTRAQ ratio (97-H SP/Hep3B SP)   iTRAQ ratio (LM3 SP/Hep3B SP)
  ------------------ --------------------------------------------------------- -------------------------------- -------------------------------- -------------------------------
  NPM_HUMAN          Nucleophosmin                                             0.76                             0.74                             0.66
  NCBP1_HUMAN        Nuclear cap-binding protein subunit 1                     0.83                             0.77                             0.63
  TIGAR_HUMAN        Fructose-2,6-bisphosphatase TIGAR                         0.83                             0.82                             0.66
  PRDX4_HUMAN        Peroxiredoxin-4                                           0.53                             0.53                             0.53
  ADIRF_HUMAN        Adipogenesis regulatory factor                            0.65                             0.56                             0.56
  CIP2A_HUMAN        Protein CIP2A                                             0.84                             0.79                             0.63
  ECI1_HUMAN         Enoyl-CoA disomerase 1, mitochondrial                     0.75                             0.72                             0.66
  ITB1_HUMAN         Integrin β-1                                              0.80                             0.79                             0.62
  PCM1_HUMAN         Pericentriolar material 1 protein                         0.81                             0.65                             0.51
  HS74L_HUMAN        Heat shock 70 kDa protein 4L                              0.87                             0.77                             0.67
  KV203_HUMAN        Igkchain V--II region MIL                                 0.62                             0.55                             0.50
  DIC_HUMAN          Mitochondrial dicarboxylate carrier                       0.98                             0.83                             0.62
  PAK2_HUMAN         Cluster of Serine/threonine-protein kinase PAK 2          0.72                             0.70                             0.58
  RBM39_HUMAN        RNA-binding protein 39                                    0.84                             0.79                             0.55
  DDX17_HUMAN        Probable ATP-dependent RNA helicase DDX17                 0.68                             0.65                             0.64
  XRCC5_HUMAN        X-ray repair cross-complementing protein 5                0.73                             0.72                             0.66
  TXTP_HUMAN         Tricarboxylate transport protein, mitochondrial           0.58                             0.55                             0.52
  SPCS2_HUMAN        Signal peptidase complex subunit 2                        0.71                             0.66                             0.56
  RM38_HUMAN         39S ribosomal protein L38, mitochondrial                  0.65                             0.59                             0.52
  PPID_HUMAN         Peptidyl-prolyl cis-trans isomerase D                     1.01                             1.10                             1.53
  SNX3_HUMAN         Sorting nexin-3                                           1.16                             1.26                             1.53
  MRP1_HUMAN         Multidrug resistance-associated protein 1                 1.26                             1.80                             2.14
  GET4_HUMAN         Golgi to ER traffic protein 4 homolog                     3.97                             4.07                             4.62
  GNL3_HUMAN         Guanine nucleotide-binding protein-like 3                 1.09                             1.43                             1.63
  DNJB1_HUMAN        DnaJ homolog subfamily B member 1                         1.34                             1.35                             1.63
  CHRD1_HUMAN        Cysteine and histidine-rich domain-containing protein 1   1.07                             1.22                             1.52
  ALDR_HUMAN         Aldose reductase                                          1.44                             1.51                             1.55
  PSD12_HUMAN        26S proteasome non-ATPase regulatory subunit 12           1.39                             1.41                             1.55
  TKT_HUMAN          Transketolase                                             1.40                             1.42                             1.59
  CERU_HUMAN         Ceruloplasmin                                             1.08                             1.33                             1.67

iTRAQ, isobaric tags for relative and absolute quantification; SP, side population.
